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Abstract
Background: Appropriate information and consent has been one of the most intensely discussed topics within the
context of biobank research. In parallel to the normative debate, many socio-empirical studies have been conducted to
gather experiences, preferences and views of patients, healthy research participants and further stakeholders. However,
there is scarcity of literature which connects the normative debate about justifications for different consent models with
findings gained in empirical research. In this paper we discuss findings of a limited review of socio-empirical research
on patients’ and healthy research participants’ experiences and views regarding consent to biobank research in light of
ethical principles for appropriate information and consent.
Methods: Review question: Which empirical data are available on research participants’ perceptions and views regarding
information and elicitation of consent for biobank research? Search of articles published till March 1st 2014 in Pubmed.
Review of abstracts and potentially relevant full text articles by two authors independently. As categories for content
analysis we defined (i) understanding or recall of information, (ii) preferences regarding information or consent, and (iii)
research participants’ concerns.
Results: The search in Pubmed yielded 337 abstracts of which 10 articles were included in this study. Approaches to
information and consent varied considerably across the selected studies. The majority of research participants opted for
some version of limited consent when being informed about such possibility. Among the factors influencing the type of
preferred consent were information about sponsoring of biobank research by pharmaceutical industry and participants’
trade-off between privacy and perceived utility. Studies investigating research participants’ understanding and recall
regarding the consent procedure indicated considerable lack of both aspects. Research participants’ perceptions of
benefits and harms differ across those studies.
Conclusion: The knowledge, perceptions and views of research participants who have undergone a consent procedure
within the context of biobank research raise several questions on the issue of how to inform and elicit consent in an
ethically acceptable way. In our empirical-ethical analysis we develop suggestions on how the practice of eliciting
consent in the biobank context should be improved.
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Background
The achievements of the Human Genome Project and
the use of technologies enabling researchers to analyze
large amounts of DNA have made biobanks an estab-
lished part of research practice [1]. Biobanks contribute
to a multitude of ongoing research projects by storing
huge amounts of biological information and data about
phenotypes, clinical aspects and also, in some cases, life-
style information, such as nutrition and exercise. One of
the earliest and most intensely discussed questions from
an ethical as well as legal perspective with regards to
biobank research is that of appropriate consent to bio-
bank research. The fact that the nature of the research
and its risks and benefits to potential participants often
cannot be disclosed in detail at the time of eliciting con-
sent has been seen by some scholars as a challenge to
“informed consent” [2–4]. According to the standard ac-
count of informed consent, individuals are considered as
sovereign with regards to decision-making about them-
selves [5]. The demand for informed consent is not a
movement stemming from within medical research or
practice, but can be better described as a development
pushed into medical practice in the form of ethico-legal
regulations—also as a reaction to various scandals in
medicine [6, 7]. In addition and connected with the birth
of bioethics in the 1960s, informed consent has been
emphasized as an antidote to paternalistic approaches in
medicine [5, 8].
The development and justification of alternative con-
sent models has been at the center of interdisciplinary
research [9–12]. On the one hand, it has been argued
that the use of informed consent as it was formerly con-
ceived is difficult to realize with the rise of new tech-
nologies related to big data and their application in
medicine (i.e. the protection of individual privacy stands
in contradiction to the gathering of data collected in big
databases). On the other hand, the roles of individuals is
more and more emphasized, for example, in the form of
regulations to protect individual rights (i.e. privacy), with
the result that scientific practices, such as population
registries, are challenged because of new laws emphasiz-
ing the use of informed consent for scientific practices
which are of benefit for local communities [13]. This
tension described previously has resulted in the develop-
ment of a strategic planning reform of science intro-
duced by the European Commission, called “Science
2.0,” or “Science in Transition” [14], strategic planning
also extended to biobanking [15], which can be charac-
terized as approaches to include the voices of all the
stakeholders (i.e. patients, citizens and researchers).
While an analysis of the multitude of models of consent
developed and their philosophical, ethical and legal foun-
dation are beyond the scope of this paper, one way of
structuring the debate is by distinguishing the forwarded
models as “narrow” versus “broad” consent to biobank re-
search. According to this distinction, the narrow consent
model shares key assumptions of informed consent, in the
sense that consent to biobank research should be specific
and based on concrete information about the research
planned [16]. As one consequence, participants who give
consent to a defined project need to be recontacted if the
biological material and/or data is intended for use in an-
other research project. Narrow (informed) consent has
been criticized for not taking the practical challenges suffi-
ciently into account, such as acquiring consent from dead
donors, drop-out rates that decrease the scientific value of
the study or substantial logistic expenses [17–19]. In
broad consent, patients or research participants give their
consent to the use of biological and/or clinical data in re-
search which is not specified at the time of consent. There
are different lines of argument in favor of such broad con-
sent. One line is that the risks of biobank research are per-
ceived to be small compared to the related benefits [20].
This risk assessment is sometimes combined with a sec-
ond argument that holds a duty of solidarity to support
medical research with such a risk-benefit ratio [21–23].
Thirdly, broad consent has been supported for prag-
matic reasons, as it appears to be the more efficient
regarding the economic and logistic aspects of bio-
bank research [24].
Narrow and broad models of consent differ in ethically
relevant aspects, mostly because a broad model of consent
confers more responsibilities on institutional bodies (e.g.
ethics committees and institutional review boards) and
justifications forwarded for limitations of information
given to the individual research participant on research
aims, risks and benefits [25]. By contrast, narrow models
of consent stress much more the role of participants’ un-
derstanding of details of the research and their individual
rights with regards to the conduct of research. Neverthe-
less, broad and narrow models of consent also share as-
sumptions. One example is that in order to give valid
consent, participants should be enabled to understand the
issues at stake [26]. In the wake of the strategic planning
of science and biobanking [14, 15], many socio-empirical
studies have been conducted during recent years to gather
the experiences, preferences and views of patients, healthy
research participants and further stakeholders with regard
to consent in the context of biobank research. However,
there is scarcity of literature which connects the norma-
tive debate about justifications for different consent
models with findings gained in socio-empirical research.
Against this background, we summarize the findings of a
limited review of socio-empirical research on patients’ and
healthy research participants’ experiences and views
regarding consent to biobank research. We focus in our
subsequent empirical-ethical analysis on findings which, in
our view, are informative to answer the question of what
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an ethically acceptable practice of informing potential
research participants and eliciting consent should look like.
Methods
In a first step, we formulated the review question: Which
empirical data are available on research participants’ per-
ceptions and views regarding information and elicitation
of consent for biobank research? For the purpose of this
review biobank was defined as structure in which human
biological and/or clinical data is stored for the purpose
of research. As the second step, we chose PubMed as
database to query. This decision was made in light of
the fact that our past work on the topic as well as the
conduct of systematic reviews on other ethical topics in-
dicates that use of this database generates the vast ma-
jority of relevant articles [27–29]. In a third step we
developed a search algorithm based on key words in
relevant conceptual and empirical studies: (consent [tw]
OR privacy [tw] OR autonomy [tw]) AND (biobank [tw]
OR genomic research [tw] OR personalised medicine
[tw] OR genomic data [tw]. In a fourth step, criteria to
determine the relevance of retrieved articles were de-
fined. These criteria are based on the review questions
as well as a sample of studies about the topic known to
the researchers prior to the review [5, 18, 30–34]. Table 1
summarises in- and exclusion criteria.
The search was limited to articles published till March
1st 2014. All titles and abstracts were read by two au-
thors (FD, JS) and a decision regarding the inclusion or
exclusion of the articles based on the predefined selec-
tion criteria was made independently. Where no abstract
was available, articles with a potentially relevant content
(as indicated by title) were ordered and the decision was
made after reading the full text. In case of disagreement
between both authors consensus was sought based on
the abstract or if necessary full text was retrieved (Fig. 1).
Content analysis
The following categories were defined prior to data analysis
with the aim of quantification of data: (i) nationality of
research participants, (ii) target groups (i.e. healthy re-
search participants, patients as research participants), (iii)
research methods (i.e. surveys, semi-structured interviews,
focus groups and other forms of group discussion). In
addition and for the purpose of qualitative content analysis
which follows basic principles as described by Mayring
[35], the following pre-defined categories were formed: (i)
understanding or recall of information, and (ii) preferences
regarding information or consent. Both categories reflect
the interest of the researchers in light of their preconceived
knowledge from the literature prior to the research. The
first category was thought as pivotal in the process of
giving an informed consent as comprehending the infor-
mation received is the very base on which taking an au-
tonomous decision and because the issue of understanding
is one of the weakest points of informed consent [5]. The
second category was ideated as it gives further indications
useful in making an informed consent process based on
preferences of research participants. In the course of the
systematic literature we added the category (iii) research
participants’ concerns. This third category was developed
in a bottom up way based on a first analysis of relevant
articles in which we identified expression of concerns from
biobank’s participants as a topic relevant for the context of
our review.
Results
The search in PubMed yielded 337 abstracts. Twenty
five full text papers were read and assessed against inclu-
sion and exclusion criteria. Of these, finally 10 articles
were included in this study [36–45]. Reasons for exclu-
sion at this stage were mainly due to lack of focus on
participants’ perceptions or views regarding information
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Research method/Type of publication
Empirical research (qualitative or quantitative) Case studies
Theoretical papers
Comments or opinion papers
Guidelines
Research participants
Research participants have been involved
in consent procedure for biobank research
Empirical research on perception or views of public or patients not involved in biobank research
Empirical research focusing paediatric genetic research (i.e. view of parents/guardian).
Topic of research
Research participants’ perception or views
on consent is central topic of the study
Studies on biobank research participants’ views or attitudes other than consent
Papers focusing on disclosure of incidental findings
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or consent, for example [Hobbs et al. [46], Ridgeway et
al. [47], Steinsbekk et al. [48], Williams et al. [49], or as
the focus was on subjects who had not been involved in
a consent procedure regarding biobank research, for ex-
ample Rahm et al. [50], or because the focus was on
consent with parents of children donors, for example
Tindana et al. [51].
Characteristic of studies and research participants
Five studies had been conducted in the U.S. [39–43]. Four
of these studies had been conducted by researcher(s) of
the Center for Medical Ethics and Health Policy, Baylor
College of Medicine, Houston, Texas [39–41, 43]. The
other studies had been conducted in Australia [38], Italy
[36], Japan [45], Spain, including a small sample from US,
[44], and Sweden [37]. Most of the studies had been con-
ducted with patients who were participating in biobank
research (N = 9) [36, 38–45]. In one of these studies re-
search participants were exclusively patients with cancer
[36]. In some studies parents of pediatric patients were in-
volved in addition [Lipworth et al. [38], McGuire et al.
[40], Oliver et al. [41], Robinson et al. [43]. The Swedish
study presents findings from a random sample of a
biobank without further information about the health sta-
tus [37]. Data collection was performed in seven studies
via structured questionnaires which in some cases in-
cluded open ended questions [36, 37, 40, 41, 43–45]. The
study by [Watanabe et al. [45] in addition to quantitative
data reports also qualitative findings but without any ac-
count of systematic gathering and analysis of the latter
kind of data. Ormond et al. [42] use a modified version of
the structured Quality of Informed Consent (QuIC) ques-
tionnaire [52] combined with a qualitative section of 12
questions on consent. Two studies used qualitative
methods [38, 39] for data gathering and analysis. Table 2
summarizes main characteristics and findings of eligible
studies.
Preferences regarding different types of consent
Five studies reported findings on preferences of research
participants regarding the mode of consent to biobank
research. Being asked about general preferences for
broader or narrower versions of consent, Valle-Mansilla
et al. [44] report that the majority (59.8 %) of the 279 re-
search participants preferred some type of limitation to
consent. In this study 29.7 % preferred to be re-
contacted in case of any new research using the donated
material and data. In contrast, Hoeyer et al. [37] report
that 85.9 % of the research participants accepted surro-
gate decision making by regional research ethics com-
mittees with regards the use of the blood donated to the
biobank. Three studies explored preferences regarding
consent with a focus on the choice between different op-
tions of data sharing [39–41]. In two of these studies
[40, 41] research participants willing to donate biological
material into one of six genome studies at Baylor College
of Medicine in Houston, randomly underwent three dif-
ferent models of consent which allowed different degrees
of choices regarding control of public data release and
data sharing. The three models of consent consisted
Records identified through Pubmed 
searching
(n=337 )










included in qualitative 
synthesis(n=10)
Fig. 1 Flow chart literature search
D’Abramo et al. BMC Medical Ethics  (2015) 16:60 Page 4 of 11
Table 2 Summary of characteristics and findings of eligible studies
Authors / Year of Publication Country Research participants Method of data collection Main findings
1. Robinson et al. 2014 [43] USA 229 patients; parents/guardian of
paediatric patients and family
members as controls
Structured interview and open
ended questions
Over 25 % of the research
participants did not remember
that they signed a informed
consent document to participate
in a genomic study. The majority
(54 %) could not correctly
identify with whom they had
agreed to share their genomic
data. Participants felt that they
understood enough to make an
informed decision.
2. Cervo et al. 2013 [36] Italy 430 cancer patients Structured questionnaire 36.5 % of research participants
indicated that they knew what a
biobank was before participating
in the study. After the multisource
informed consent procedure more
than 95 % of patients were aware
of participating in a biobank
project subsequent to the consent
procedure.The final assessment
showed more than 95 % correct
answers. The information received
was judged to be “very
understandable” by 44.9 % and
“fairly understandable” by 53.8 %
of the research participants.
3. Oliver et al. 2012 [41] USA 229 patients; parents/guardian of
paediatric patients and family
members as controls
Structured interview and open
ended questions
Subsequent to information about
three different types of consent
with different scopes for data
sharing, research participants in
all three groups indicated that
they would be more restrictive
compared with their actual
decision before debriefing.
Qualitative findings support the
more skeptical view on data
sharing subsequent to being
informed about different options
of consent with limits to data
sharing. Research participants’
trade-off regarding privacy and
utility of research was significantly
associated with participants’
decision about data release
subsequent to debriefing.
4. McGuire et al. 2011 [40] USA 336 participants,parents/guardian
of paediatric patients and family
members as controls made initial
data release decision prior to be
informed about different consent
options. 323 research participants
made final data release decisions
subsequent to debriefing.
Structured interview on data
release decision and socio-
demographic data.
Before being informed about
different consent options 83.9 %
of participants chose public data
release. After debriefing, 53.1 %
chose public data release, 33.1 %
chose restricted (controlled access
database) release, and 13.7 %
opted out of data sharing. Hispanic
background, not being married
and college degree were
associated with choice for
restricted data release.
5. Watanabe et al. 2011 [45] Japan 1378 patients Structured questionnaire (in





research was judged as
understandable in 76.8 %
subsequent to personal
discussion compared to 60 %
after information via brochures
and 56.9 % via DVD. Interest in
personal data was positively
associated with better recall rate,
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Table 2 Summary of characteristics and findings of eligible studies (Continued)
in younger patients, higher
satisfaction with consent process
and with willingness to
participate in future study.
Research coordinators indicate
need among research
participants to get more
information following consent
procedure.
6. Valle-Mansilla 2010 [44] Spain (USA) 279 patients (30 patients from US
sample)
Structured questionnaire 230 patients (82.4 %) remembered
giving consent to biobank
research. 40.3 % preferred general
consent for future use of sample,
49.8 % preferred limited or
specified consent. Support for
broad consent was less supported
in industry-sponsored research.
7. Lipworth et al. 2009 [38] Australia 12 patients, parents of patients




use of material/data subsequent
to participation in biobank
research. There was evidence for
expectation regarding direct
benefit of research for research
participants and little awareness
of harm.
8. Ormond et al. 2009 [42] USA 200 patients Structured interviews including
open ended question
The best understood domains
included the nature of the study,
benefit to future patients, and
the voluntary nature of
participation. Lower knowledge
scores included potential risks
and discomforts, experimental
nature of the research,
procedures in the event of study-
related injury, and confidentiality
issues. Only 10 % of participants
explicitly stated they had
noexpectations for personal
benefit.
9. McGuire et al. 2008 [39] USA 15 patients and controls from a
genomic study on epilepsy
Focus groups including one
Follow up focus group with
presentation and discussion of
findings from initial focus groups.
There was a general interest in
receiving information and
making decisions about data
sharing. Participants preferred
multiple data sharing options.
However, they were more likely
to consent to public data release
when given fewer options. Most
participants felt that genomic
information should not be
publicly released without explicit
consent from research
participants.
10. Hoyer et al. 2005 [37] Sweden 930 research participants Structured questionnaire 64.5 % of participants were
aware that they had consented
to donate a blood sample,
55.4 % thought that they had
consented to donate phenotypic
information, and 31.6 % believed
that they could withdraw their
consent. 85.9 % acceped
surrogate decision making by
regional research ethics
committees.
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either of giving consent to public data release without
alternative (i), a choice between consent to public data
release and no release (ii), or a choice between consent
to public data release, restricted release only or no re-
lease at all (iii). In a follow up visit research participants
were informed about all options of data sharing. Follow-
ing this information 30.8 % less participants than initially
consented to public data release (83.9 % versus 53.1 %),
33.1 % chose restricted data release and 13.7 % did not
consent to data sharing [40]. The analysis of data on at-
titudes to consent of research participants following the
disclosure of three different consent options has been
published in a separate paper by Oliver et al. [41]. This
study indicates that research participants’ attitudes to
data sharing are even more restrictive after they had
been informed about different options regarding data
sharing than their actual choice and this had been docu-
mented in the study by McGuire et al. [40]. The quanti-
tative findings are corroborated by a qualitative focus
group study by McGuire et al. [39]. Here, participants
indicated a more restrictive approach towards public
data sharing if they received information about different
options for control of data. This study shows also that
most of the participants who had provided material and
clinical data did not support data sharing without expli-
cit consent.
Factors possibly influencing research participants pref-
erences on different types of consent have been explored
in the study of Valle-Mansilla et al. [44]. This study indi-
cates that the information about sponsoring of biobank
research by pharmaceutical industry was associated
negatively with a preference for broad consent. In
addition, Oliver et al. [41] show that decisions about the
degree of sharing of data were statistically significant as-
sociated with research participants’ trade-off between
privacy and perceived utility of data sharing. In their
study on views of Swedish biobank’s research partici-
pants, Hoeyer et al. [37] report that positive experiences
with healthcare services and satisfaction with informa-
tion about the biobank were associated with acceptance
of surrogate decision making about the use of biological
data by research ethics committees.
Recall and understanding
Five studies investigated patients’ recall or understanding
following information and consent [36, 37, 42, 43, 45]. A
general finding of these studies was lack of recall and
understanding with regards to the given consent in dif-
fering proportions of the research participants. Using
data generated in study with an experimental design of
three different consent options randomly used for a U.S.
biobank’s recruitment of research participants among
patients (see above McGuire et al. [40], Oliver et al. [41],
Robinson et al. [43] report that following the procedure
of randomly assigned consent 25 % of the whole sample
did not recall to have signed a consent form on partici-
pation in a genomic study. Furthermore, the majority
(54 %) of research participants could not correctly report
whom they had allowed to share the data with. In a simi-
lar direction point the data of Hoeyer et al. [37] who
report that only 64.5 % of research participants in a
Swedish biobank were aware of having consented to
donate a blood sample, and 54 % did remember that
they provided medical information by means of a ques-
tionnaire. Just 31.6 % knew that they could withdraw
their consent. In the study of Watanabe and colleagues a
third of participants (34.9 %) did not recall the contents
of the consent procedure [45].
The study of Watanabe et al. [45] also reports findings
about perceived understanding of the content of informa-
tion provided as part of the consent procedure following
three modes of conveying information about the research
(DVD, brochure or personal discussion with researchers).
Highest marks for understanding of the information about
the biobank research were reported by participants after
having personal discussion with the researchers. However,
qualitative information reported back from the biobank
researchers, who as part of the consent procedure
informed the research participants, suggests that there is a
perceived need to clarify information regarding the pur-
pose of the research after they had given consent (“For
what am I participating?”). The study of Ormond et al.
[42] provides a detailed analysis with regards to under-
standing of information for different domains. By use of
the “Quality of informed consent questionnaire (QuIC)”
[52] and semi-structured questions the authors identify
higher scores of understanding of research participants
with regards to the nature of the study, benefit to future
patients and the voluntary nature of participation. In con-
trast, research participants had lower knowledge scores
with regards to potential risks and discomforts and the
experimental nature of the research [42].
Cervo et al. [36] conducted the only intervention study
in the sample of eligible articles for this review. The au-
thors tested knowledge relevant to biobank research be-
fore and after a multisource informed consent procedure.
The intervention consisted of an “enhanced consent form”
and an information leaflet combined with two discussions
between the potential biobank research participants and a
physician and either a biobank-nurse or a biobank-
biologists. While only 36.5 % knew what a biobank was
before participating in the study, after this consent pro-
cedure knowledge about the purpose of the biobank and
use of collected material was higher (>90 %).
Expectations of benefits and perception of risks
Three of the eligible studies collected data on research
participants’ expectations and perceptions regarding
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benefits and risks of the research and concerns related
to biobanking. In the study by Ormond et al. [42] 10 %
indicated having no expectation with regards to person-
ally benefiting from research biobank’s findings, whereas
Oliver et al. [41] report that 14.3 % ranked benefit of
findings for research participants or family members as
most important. In the study by Ormond et al. [42] 81 %
agreed with the statement that the research was associ-
ated with no risk and discomfort. Seven per cent of the
research participants were able to identify that learning
potential genetic test results could be associated with
risks [42]. Qualitative data analysed in this study, and
also in the study of Oliver et al. [41] supports the quan-
titative findings on the difficulties of research partici-
pants to identify risks associated with the biobank
research. In the qualitative study by Lipworth et al. [38]
perceptions of trust and benefit dominated the narratives
in comparison with the perception of informational risks.
Discussion
This paper summarizes and analyzes data from socio-
empirical studies on consent to biobank research. In com-
parison to a recently published systematic review [53], our
paper focuses on the perceptions and preferences of
research participants who underwent the consent proced-
ure. Data on the views and preferences of participants in
biobank research cannot be translated directly into ethical
guidance [54]. However, experiences with the consent pro-
cedure and considerations made in this context can
provide valuable insight which, in combination with
normative analysis, can inform the debate about an
ethically acceptable approach towards the practice of
consent [55].
Our review suggests that there are two important issues
related to how ethically acceptable consent can be elicited
in research practice beyond the focus of the theoretical lit-
erature on justifications of broader or narrower approaches
to consent. Firstly, the choices provided as part of the con-
sent procedure, and secondly, the way in which potential
research participants are informed about biobank research.
1. Offering a choice to research participants for an
individualized consent
From a series of qualitative and quantitative empirical
research projects conducted by researchers of the
Center for Medical Ethics and Health Policy, Baylor
College of Medicine, Houston, Texas [39–41, 43] it
could be shown that research participants are
influenced in their decisions by the number of options
presented as part of the consent procedure. All
studies indicate that a considerable proportion of
research participants chooses restricted or no data
sharing after having learned that they can choose
between a tiered form of consent compared to
“traditional consent” (term used by the authors in this
study) according to which the participants are
requested to give broad consent or not to participate
at all in the research. The fact that the three
quantitative studies [40, 41, 43] were conducted with
only one sample of research participants and focus on
the question of consent for data sharing has to be
taken into account as a limitation with regards to the
representativeness of the findings. However, we argue
that research participants should have a choice of
scopes, for example, regarding the sharing of data.
First of all, the confrontation with different consent
options can be seen as one way to inform research
participants about aspects which are less thought of
by lay people, such as informational risks associated
with biobank research. Secondly, such an approach
acknowledges that individuals differ with regards to
risk/benefit assessment relevant to decisions about
participation in biobank research
2. Improving research participants’ understanding of
risks
The inability of research participants to recall
information on biobank research and limited
understanding with regard to the risks is a common
feature of several studies included in this review.
Limited recall or understanding is also a leitmotif of
socio-empirical research on consent in the context
of non-biobank research [56–59]. One particular
challenge for research participants’ understanding
may be that the benefits and risks in biobank re-
search are asymmetrically distributed: Risks deriving
from biobank research are of an individual and soci-
etal nature, whereas benefits are mainly for society
as a whole, as biobank research does not usually
produce any direct ready-made return for the donor.
Potential risks are mainly represented by misuses of
personal medical information resulting in possible
discrimination and stigmatization. The knowledge of
a person’s genetic makeup, for instance, can be used
to justify unequal treatment: A candidate for a job
may be excluded on the grounds of their genetic dis-
position to a future disease, or a person wishing to
buy health insurance could be refused on genetic
grounds [60]. Moreover, when participants in biobank
research believe in a direct medical gain from the
research activity itself, they incur a “therapeutic
misconception” [61]. Therefore, the consent process
for biobank research refers necessarily to an indi-
vidual evaluation of individual risks and societal
benefits [62]. The empirical data indicate that
(non-existent) individual benefits are overesti-
mated (i.e. therapeutic misconception), while
many research participants are not aware that
there are any risks at all (see, for example,
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Ormond et al. [42]. Given the abstract and com-
plex nature of risks that could derive from biobank re-
search, it seems ethically appropriate to offer such
information to potential research participants in a way
which allows them to decide whether they wish to
receive more detailed information or not. A concrete
measure in this respect would be to provide an
electronic reminder, which summarizes information
about the nature of biobank research to which they
have consented, combined with an update on concrete
research conducted or planned in the near future. This
may provide research participants with an opportunity
to learn more about what is done and to reconsider
their initial decision(s) if they wish to do so. One of the
models proposed to go beyond one-off static consent
and to allow biobank participants to decide over time
is dynamic consent, that is, a patient-centered approach
with mechanisms of governance realized through infor-
mation and communication technologies (ICT) solu-
tions to allow participants to engage as much as they
choose [63]. This approach should be contextualized
within specific cultural and social settings (e.g. privacy
laws could vary broadly between countries) and within
specific networks and consortia [11]. Dynamic consent
is a nuanced consent model, as it lets research partici-
pants go beyond the “all or nothing” option. Exemplar-
ily, participants might control different privacy settings
as flows of their personal information through a web
interface, i.e. participants can decide who is allowed to
access their de-identified information or who can have
access to their contact information. Among the advan-
tages of this approach, it is worth highlighting an
improvement of public trust and an overcoming of the
perennial issue of consent form length and comprehen-
sion—participants could, indeed, receive feedback on
the general outcomes of the project. A dynamic
consent approach can also improve transparency and
accountability in the research processes: researchers
can gather phenotypical information through continu-
ous contact with patients that, in turn, by reducing
research biases, can make the outcomes of research
more effective and reliable [64]. Arguments against
the dynamic consent approach are (i) its comparably
greater management costs, which might not be
feasible for less well funded groups or may escalate for
very large research collaborations,, and (ii) its focus on
ICT that, when exaggerated, could foster neither a
dialogical interaction nor an enhancement of cognitive
abilities of participants. In the wake of a dynamic
consent approach, it would be ethically sound to
address the wishes of biobank research participants,
letting them deciding on issues that could influence
their lives, for instance, allowing the control of fluxes of
their personal information.
As pointed out in the study of Watanabe et al. [45]
and, in particular, in the pre-post study of Cervo et
al. [36], the implementation of consent as a dia-
logical process supported by multisource informa-
tion may be a measure to inform those patients who
are interested more effectively. Given the huge
technological input into biobank infrastructure, it is
surprising how few innovative steps have been taken
to test and evaluate measures to improve the con-
sent procedures [25] and how little participants’
involvement has been developed to make biobank
research sustainable [15]. According to the knowledge
and practical experience of the authors, information
about highly sophisticated biobank research is often
provided in the form of a thick bundle of papers. Such
research practice raises questions about setting prior-
ities. Given the evidence on the impact of a more dif-
ferentiated and enhanced approach towards
information and consent [25], we argue that resources
should not only be allocated to interdisciplinary re-
search which take into account recent normative and
empirical analysis on the issue of consent and biobank
research, but also focus on the translation of these find-
ings into an ethically acceptable research practice.
Limitations
For reasons due to design of the study (i.e. selection of
articles operated through a specific algorithm and
through specific criteria as choosing only those studies
where an informed consent was performed) and not
least because a considerable amount of biobank research
and accompanying ethico, legal and social studies are
performed in Western countries, our results do not
include socio-empirical data from the so-called ‘develop-
ing countries’ – the only article retrieved through our
PubMed search on biobanking in developing countries
has been excluded as not focused on informed consent
[65]. This characteristic represents a limitation, as a
review on socio-empirical literature about biobanking in-
cluding data from developing countries would be of help
to better understand implications for the conduct of
consent in culture where there is, for example, an em-
phasis on oral communication and oral consent [66].
Furthermore, an analysis of biobanking in developing
counties might be of help to foster policies around indi-
vidual rights (i.e. the principle of individual autonomy),
to activate mechanisms of citizenship consensus [67]
and to encourage processes of community/public con-
sultation [68]. In addition such research may be also
relevant for the conduct of research in western countries
where a more dialogical/oral approach communication
could be considered as improvement to some of the cur-
rently used approaches. Moreover, this review of ten
studies with differing sample size and methodology
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provides a limited insight into socio-empirical data on
consent as perceived and viewed by research partici-
pants. More studies might have gained by using other
databases and auxiliary search strategies. Due to limited
resources and in light of the findings gained out of the
retrieved studies we decided to limit our search strategy.
Given that all studies stem from developed countries,
and that 4 out of 10 studies are from a single center
located in United States, where biobanking is a well-
established practice, the findings of this review cannot
be extrapolated to current biobank research in less
developed or transitional countries or countries with dif-
ferent cultural values and a special attention should be
paid for those countries with different traditions around
informed consent for medical research.
Conclusion
In recent years great parts of the discussion on ethical
and legal aspects of consent for biobank research has
focused on justifications for broader and narrower con-
sent models [69]. The findings of this review suggest
that, consent models which offer a more nuanced ap-
proach including choices of degrees to give or withhold
consent to parts of biobank research reflect the prefer-
ences and views of research participants better than ap-
proaches which offer little choice regarding the scope of
consent. In light of the lack of recall and limited under-
standing of information among research participants, re-
search on the implementation and evaluation of
improved consent procedures should be a priority. The
rising use of information technologies in the context of
evidence based decision support tools, as well as process
oriented approaches towards information and consent
are only two of several concrete examples which could
serve the aim of informing potential biobank research
participants appropriately about the issues at stake.
Competing interests
The authors declare that there are no competing interests.
Authors’ contribution
FD, JS and JV designed the research project. FD and JS conducted the
empirical review. All authors developed the main arguments of this article.
FD and JS drafted the manuscript. JV critically revised the manuscript. All
authors have read and approved the final manuscript.
Acknowledgement
The work of Jan Schildmann and Jochen Vollmann has been conducted as part
of the collaborative research network ‘Personalised Medicine in Oncology: An
Interdisciplinary Study on Ethical, Medical, Economical and Legal Aspects’ (Grant
project number: 01 GP 1001A-C), which has been supported by the German
Federal Ministry of Education and Research (Bundesministerium für Bildung
und Forschung—BMBF). Flavio D’Abramo conducted this work as part of an
International Visiting Fellowship in Medical Ethics at the Institute for Medical
Ethics and History of Medicine, Ruhr-University Bochum. The authors acknowledge
support by the German Research Foundation and the Open Access Publication
Funds of the Ruhr-Universität Bochum.
Author details
1Institute for Medical Ethics and History of Medicine, Ruhr-Universität
Bochum, Markstraße 258a, D-44799 Bochum, Germany. 2Charité
Comprehensive Cancer Center, Charité - Universitätsmedizin, Charitéplatz 1,
Berlin D-10117, Germany.
Received: 14 March 2015 Accepted: 26 August 2015
References
1. Hilgartner S. Making maps and making social order. Governing American
genome centers, 1988-93. In: Gaudilliere JP, Rheinberger HJ, editors. From
molecular genetics to genomics. The mapping cultures of twenty-century
genetics. London and New York: Routledge; 2004. p. 113–28.
2. Mauron A. Biobanks, genomic and research. A nighmare for public policy
makers? In: Elger B, Biller-Andorno N, Mauron A, Capron AM, editors. Ethical issues
in governing biobanks. Global perspectives. Hampshire, UK: Ashgate; 2008. p. 1–9.
3. Scott CT, Caulfield T, Borgelt E, Illes J. Personal medicine—the new banking
crisis. Nat Biotechnol. 2012;30(2):141–7. doi:10.1038/nbt.2116.
4. Browman GP, Vollmann J, Virani A, Schildmann J. Improving the quality of
‘personalized medicine’ research and practice: through an ethical lens. Pers
Med. 2014;11(4):413–23. doi:10.2217/pme.14.17.
5. Dawson A. Informed consent: should we really insist upon it? New review
of bioethics. 2003;1(1):59–71. doi:10.1080/1740028032000131422.
6. Vollmann J, Winau R. Informed consent in human experimentation before
the Nuremberg code. BMJ (Clinical research ed). 1996;313(7070):1445–9.
7. Sass HM. Reichsrundschreiben 1931: pre-Nuremberg German regulations
concerning new therapy and human experimentation. J Med Philos.
1983;8(2):99–111.
8. Jonsen A. The Birth of Bioethics. USA: Oxford University Press; 1998.
9. Caulfield T, Upshur RE, Daar A. DNA databanks and consent: a suggested
policy option involving an authorization model. BMC Med Ethics. 2003;4:E1.
10. Hofmann B, Solbakk JH, Holm S. Consent to Biobank Research: One Size Fits
All? In: Solbakk JH, Holm S, Hofmann B, editors. The Ethics of Research
Biobanking. New York: Springer US; 2009. p. 3–23.
11. Kaye J, Whitley EA, Lund D, Morrison M, Teare H, Melham K. Dynamic
consent: a patient interface for twenty-first century research networks. Eur J
Hum Genet. 2014. doi:10.1038/ejhg.2014.71.
12. Stein DT, Terry SF. Reforming biobank consent policy: a necessary move
away from broad consent toward dynamic consent. Genet Test Mol
Biomarkers. 2013;17(12):855–6. doi:10.1089/gtmb.2013.1550.
13. Casali PG. Risks of the new EU Data Protection Regulation: an ESMO position
paper endorsed by the European oncology community. Ann Oncol.
2014;25(8):1458–61. doi:10.1093/annonc/mdu218.
14. European Commission. Background document: Public Consultation ‘Science
2.0’: Science in Transition. Directorates-General for Research and Innovation
(RTD) and Communications Networks, content and Technology (CONNECT).
2014. http://ec.europa.eu/research/consultations/science-2.0/
background.pdf.Accessed 05/09/2015.
15. Simeon-Dubach D, Henderson MK. Sustainability in biobanking. Biopreserv
Biobank. 2014;12(5):287–91. doi:10.1089/bio.2014.1251.
16. Gaskell G, Gottweis H, Starkbaum J, Gerber MM, Broerse J, Gottweis U, et al.
Publics and biobanks: Pan-European diversity and the challenge of responsible
innovation. Eur J Hum Genet. 2013;21(1):14–20. doi:10.1038/ejhg.2012.104.
17. Greely HT. Breaking the stalemate: a prospective regulatory framework for
unforseen research uses of human tissue samples and health information.
Wake Forest Law Review. 1999;34(3):737–66.
18. Hansson MG, Dillner J, Bartram CR, Carlson JA, Helgesson G. Should donors
be allowed to give broad consent to future biobank research? Lancet
Oncol. 2006;7(3):266–9. doi:10.1016/s1470-2045(06)70618-0.
19. Helgesson G, Dillner J, Carlson J, Bartram CR, Hansson MG. Ethical
framework for previously collected biobank samples. Nat Biotechnol.
2007;25(9):973–6. doi:10.1038/nbt0907-973b.
20. Hansson MG, Levin M. Biobanks as resources for health. Uppsala: Research
Program Ethics in Biomedicine; 2003.
21. Chadwick R, Berg K. Solidarity and equity: new ethical frameworks for
genetic databases. Nat Rev Genet. 2001;2(4):318–21. doi:10.1038/35066094.
22. Hoedemaekers R, Gordijn B, Pijnenburg M. Solidarity and justice as guiding
principles in genomic research. Bioethics. 2007;21(6):342–50. doi:10.1111/
j.1467-8519.2007.00562.x.
D’Abramo et al. BMC Medical Ethics  (2015) 16:60 Page 10 of 11
23. Knoppers BM, Chadwick R. Human genetic research: emerging trends in
ethics. Nat Rev Genet. 2005;6(1):75–9. doi:10.1038/nrg1505.
24. Petrini C. “Broad” consent, exceptions to consent and the question of using
biological samples for research purposes different from the initial collection
purpose. Soc Sci Med. 2010;70(2):217–20. doi:10.1016/j.socscimed.2009.10.004.
25. Kohnen T, Schildmann J, Vollmann J. Patients’ self-determination in
“personalised medicine”: The case of whole genome sequencing and tissue
banking in oncology. In: Braun M, Dabrock P, editors. Individualised
Medicine “between hype und hope”. Münster: LIT; 2013. p. 97–110.
26. Beauchamp TL. Informed consent: its history, meaning, and present challenges.
Camb Q Healthc Ethics. 2011;20(4):515–23. doi:10.1017/s0963180111000259.
27. Schildmann E, Schildmann J. Palliative sedation therapy: a systematic literature
review and critical appraisal of available guidance on indication and decision
making. J Palliat Med. 2014;17(5):601–11. doi:10.1089/jpm.2013.0511.
28. Schildmann J. Decisions about limiting treatment in cancer patients. A
systematic review and clinical-ethical analysis of reported variables. J Palliat
Med. 2015. doi:10.1089/jpm.2014.0441.
29. Schildmann J, Vollmann J. Evaluation of clinical ethics consultation: a
systematic review and critical appraisal of research methods and outcome
criteria. In: Gordon PDJS, Vollmann PJ, Schildmann J, editors. Clinical Ethics
Consultation: Theories and Methods. Implementation: Evaluation. Ashgate
Publishing Limited; 2013. p. 203–15.
30. Boniolo G, Di Fiore PP, Pece S. Trusted consent and research biobanks:
towards a ‘new alliance’ between researchers and donors. Bioethics.
2012;26(2):93–100. doi:10.1111/j.1467-8519.2010.01823.x.
31. Cambon-Thomsen A, Rial-Sebbag E, Knoppers BM. Trends in ethical and
legal frameworks for the use of human biobanks. Eur Respir J.
2007;30(2):373–82. doi:10.1183/09031936.00165006.
32. Hofmann B. Broadening consent—and diluting ethics? J Med Ethics.
2009;35(2):125–9. doi:10.1136/jme.2008.024851.
33. Mascalzoni D, Hicks A, Pramstaller P, Wjst M. Informed consent in the
genomics era. PLoS Med. 2008;5(9):e192. doi:10.1371/journal.pmed.0050192.
34. Sheehan M. Can broad consent be informed consent? Public Health Ethics.
2011;4(3):226–35. doi:10.1093/phe/phr020.
35. Philipp M. Qualitative inhaltsanalyse. Forum Qualitative Sozialforschung/
Forum: Qualitative Social Research. 2000;1(2):Art. 20.
36. Cervo S, Rovina J, Talamini R, Perin T, Canzonieri V, De Paoli P, et al. An
effective multisource informed consent procedure for research and clinical
practice: an observational study of patient understanding and awareness of
their roles as research stakeholders in a cancer biobank. BMC Med Ethics.
2013;14:30. doi:10.1186/1472-6939-14-30.
37. Hoeyer K, Olofsson BO, Mjorndal T, Lynoe N. The ethics of research using
biobanks—reason to question the importance attributed to informed
consent. Arch Intern Med. 2005;165(1):97–100. doi:10.1001/archinte.165.1.97.
38. Lipworth W, Morrell B, Irvine R, Kerridge I. An empirical reappraisal of public
trust in biobanking research: rethinking restrictive consent requirements.
J Law Med. 2009;17(1):119–32.
39. McGuire AL, Hamilton JA, Lunstroth R, McCullough LB, Goldman A.
DNA data sharing: research participants’ perspectives. Genet Med.
2008;10(1):46–53. doi:10.1097/GIM.0b013e31815f1e00.
40. McGuire AL, Oliver JM, Slashinski MJ, Graves JL, Wang T, Kelly PA, et al. To share
or not to share: a randomized trial of consent for data sharing in genome
research. Genet Med. 2011;13(11):948–55. doi:10.1097/GIM.0b013e3182227589.
41. Oliver JM, Slashinski MJ, Wang T, Kelly PA, Hilsenbeck SG, McGuire AL. Balancing
the risks and benefits of genomic data sharing: genome research participants’
perspectives. Public Health Genomics. 2012;15(2):106–14. doi:10.1159/000334718.
42. Ormond KE, Cirino AL, Helenowski IB, Chisholm RL, Wolf WA. Assessing the
understanding of biobank participants. Am J Med Genet A. 2009;149A(2):188–98.
doi:10.1002/ajmg.a.32635.
43. Robinson JO, Slashinski MJ, Wang T, Hilsenbeck SG, McGuire AL.
Participants’ recall and understanding of genomic research and large-
scale data sharing. J Empir Res Hum Res Ethics. 2013;8(4):42–52.
doi:10.1525/jer.2013.8.4.42.
44. Valle-Mansilla JI, Ruiz-Canela M, Sulmasy DP. Patients’ attitudes to informed
consent for genomic research with donated samples. Cancer Invest.
2010;28(7):726–34. doi:10.3109/07357907.2010.494320.
45. Watanabe M, Inoue Y, Chang C, Hong H, Kobayashi I, Suzuki S, et al. For
what am I participating? The need for communication after receiving
consent from biobanking project participants: experience in Japan. J Hum
Genet. 2011;56(5):358–63. doi:10.1038/jhg.2011.19.
46. Hobbs A, Starkbaum J, Gottweis U, Wichmann HE, Gottweis H. The privacy-
reciprocity connection in biobanking: comparing German with UK strategies.
Public Health Genomics. 2012;15(5):272–84. doi:10.1159/000336671.
47. Ridgeway JL, Han LC, Olson JE, Lackore KA, Koenig BA, Beebe TJ, et al. Potential
bias in the bank: what distinguishes refusers, nonresponders and participants in
a clinic-based biobank? Public Health Genomics. 2013;16(3):118–26. doi:10.1159/
000349924.
48. Steinsbekk KS, Ursin LO, Skolbekken JA, Solberg B. We’re not in it for the
money-lay people’s moral intuitions on commercial use of ‘their’ biobank.
Med Health Care Philos. 2013;16(2):151–62. doi:10.1007/s11019-011-9353-9.
49. Williams PH, Nemeth LS, Sanner JE, Frazier LQ. Thematic analysis of cardiac
care patients’ explanations for declining contribution to a genomic research-
based biobank. Am J Crit Care. 2013;22(4):320–7. doi:10.4037/ajcc2013838.
50. Rahm AK, Wrenn M, Carroll NM, Feigelson HS. Biobanking for research: a
survey of patient population attitudes and understanding. J Community
Genet. 2013;4(4):445–50. doi:10.1007/s12687-013-0146-0.
51. Tindana P, Bull S, Amenga-Etego L, de Vries J, Aborigo R, Koram K, et al.
Seeking consent to genetic and genomic research in a rural Ghanaian
setting: a qualitative study of the MalariaGEN experience. BMC Med Ethics.
2012;13:15. doi:10.1186/1472-6939-13-15.
52. Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent:
a new measure of understanding among research subjects. J Natl Cancer
Inst. 2001;93(2):139–47.
53. Khan A, Capps BJ, Sum MY, Kuswanto CN, Sim K. Informed consent for
human genetic and genomic studies: a systematic review. Clin Genet.
2014;86(3):199–206. doi:10.1111/cge.12384.
54. Salloch S, Vollmann J, Schildmann J. Ethics by opinion poll? The functions of
attitudes research for normative deliberations in medical ethics. J Med
Ethics. 2014;40(9):597–602. doi:10.1136/medethics-2012-101253.
55. Salloch S, Schildmann J, Vollmann J. Empirical research in medical ethics: how
conceptual accounts on normative-empirical collaboration may improve
research practice. BMC Med Ethics. 2012;13:5. doi:10.1186/1472-6939-13-5.
56. Bergler JH, Pennington AC, Metcalfe M, Freis ED. Informed consent: how
much does the patient understand? Clin Pharmacol Ther. 1980;27(4):435–40.
57. Cassileth BR, Zupkis RV, Sutton-Smith K, March V. Informed consent—why
are its goals imperfectly realized? N Engl J Med. 1980;302(16):896–900.
doi:10.1056/nejm198004173021605.
58. Estey A, Wilkin G, Dossetor J. Are research subjects able to retain the
information they are given during the consent process? Health Law Review.
1994;3(2):37–41.
59. Hassar M, Weintraub M. “Uniformed” consent and the wealthy volunteer: an
analysis of patient volunteers in a clinical trial of a new anti-inflammatory
drug. Clin Pharmacol Ther. 1976;20(4):379–86.
60. Ethikrat N. Human biobanks for research. Berlin: The German National Ethics
Council; 2010.
61. Henderson GE, Churchill LR, Davis AM, Easter MM, Grady C, Joffe S, et al.
Clinical trials and medical care: defining the therapeutic misconception.
PLoS Med. 2007;4(11):e324. doi:10.1371/journal.pmed.0040324.
62. Hoeyer K. Ambiguous gifts. Public anxiety, informed consent and biobanks.
In: Tutton R, Corrigan O, editors. Genetic databases. Socio-ethical issues in
the collection and use of DNA. London: Taylor & Francis; 2004. p. 97–116.
63. Terry SF, Shelton R, Biggers G, Baker D, Edwards K. The haystack is made of needles.
Genet Test Mol Biomarkers. 2013;17(3):175–7. doi:10.1089/gtmb.2012.1542.
64. Li AM, Terry SF. Linking personal health data to genomic research. Genet
Test Mol Biomarkers. 2015;19(1):1–2. doi:10.1089/gtmb.2015.1562.
65. Barr M, Souan L, MacGabhann P, Muller J, Al Ashhab M, Jasser M, et al. The
establishment of an ISO compliant cancer biobank for Jordan and its
neighboring countries through knowledge transfer and training. Biopreserv
Biobank. 2014;12(1):3–12. doi:10.1089/bio.2013.0072.
66. Onvomaha Tindana P, Kass N, Akweongo P. The informed consent process
in a rural African setting: a case study of the Kassena-Nankana district of
Northern Ghana. IRB. 2006;28(3):1–6.
67. Ahram M, Othman A, Shahrouri M. Public support and consent preference
for biomedical research and biobanking in Jordan. Eur J Hum Genet. 2012.
doi:10.1038/ejhg.2012.213.
68. Rotimi C, Leppert M, Matsuda I, Zeng C, Zhang H, Adebamowo C, et al.
Community engagement and informed consent in the International HapMap
project. Community Genet. 2007;10(3):186–98. doi:10.1159/000101761.
69. D'Abramo F. Biobank research, informed consent and society. Towards a new
alliance? J Epidemiol Community Health. 2015. doi:10.1136/jech-2014-205215.
D’Abramo et al. BMC Medical Ethics  (2015) 16:60 Page 11 of 11
